复发/难治性多发性骨髓瘤中 CAR-T 细胞治疗增强血小板功能

The influence of chimeric antigen receptor T (CAR-T) cell therapy on platelet function in relapsed/refractory (R/R) multiple myeloma (MM) has not been thoroughly investigated.

Our cohort comprised fifty MM patients treated with CAR-T cells. The mean platelet closure time (PCT) induced by collagen/adenosine diphosphate (CADP) in peripheral blood was significantly prolonged before lymphodepletion (195. 24 11. 740 s) and notably reduced post-CAR-T cell therapy (128. 02 5. 60 s), with a statistically significant improvement (67. 22, 95% CI 46. 91-87. 53, P < 0. 001). This post-treatment PCT was not significantly different from that of healthy controls (10. 64, 95% CI 1. 11-22. 40, P > 0. 05).

Furthermore, a pronounced enhancement in PCT was observed in patients with a response greater than partial remission (PR) following CAR-T cell infusion compared to pre-treatment values (P < 0. 001). An extended PCT was also associated with a less favorable remission status. In patients with cytokine release syndrome (CRS) grades 0-2, those with a PCT over 240. 5 s exhibited a shorter progression-free survival (PFS), with median PFS times of 10.

2 months for the PCT > 240. 5 s group versus 22. 0 months for the PCT 240. 5 s group. Multivariate analysis revealed that a PCT value exceeding 240. 5 s is an independent prognostic factor for overall survival (OS) in R/R MM patients after CAR-T cell therapy. The study demonstrates that CAR-T cell therapy enhances platelet function in R/R MM patients, and PCT emerges as a potential prognostic biomarker for the efficacy of CAR-T cell therapy.